Kinfo
Q32 Bio Inc. logo

Q32 Bio Inc.

QTTBNASDAQHealthcare·US · USD
$8.71
-0.11 (-1.25%)
Prices as of November 13, 2026 · market closed

Price

Key statistics

Valuation
Market cap260.64M USD
Enterprise value-20.54M USD
Trailing P/E2.45
Forward P/E-8.65
PEG ratio-0.06
Price / sales4.91
Price / book0.92
Profitability
Gross margin0.00%
Operating margin34.20%
Profit margin60.02%
Return on assets6.47%
Return on equity23.96%
Income (TTM)
Revenue53.74M USD
Gross profit37.80M USD
EBITDA19.57M USD
Net income32.25M USD
Diluted EPS$3.60
Rev. growth (YoY)0.00%
Balance sheet
Total cash289.59M USD
Total debt5.12M USD
Debt / equity1.78
Current ratio56.34
Book value / share$9.62
Cash flow (TTM)
Operating cash flow-20.02M USD
Levered free cash flow19.48M USD
Shares & price
Shares outstanding29.76M
Float13.67M
Held by institutions95.96%
Beta-0.11
50-day MA$9.39
200-day MA$9.44
52-week high$23.57
52-week low$1.91
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-11-04-0.33-0.26+21.21%2026-08-05-0.54-0.44+18.52%2026-06-24-0.02-0.02+0.00%2026-05-05-0.68-0.54+20.59%2026-03-162.012.62+30.35%
About Q32 Bio Inc.

Q32 Bio Inc. is a clinical-stage biotechnology company focused on developing biologic therapies for autoimmune and inflammatory diseases driven by immune system dysfunction. The company’s current programs center on restoring healthy immune balance through targeted modulation of the adaptive and innate immune systems, with a lead emphasis on treatments for alopecia areata and other immune-mediated conditions. Q32 Bio’s pipeline includes bempikibart, an antibody-based candidate designed to regulate immune signaling in dermatology and related autoimmune settings, as well as research efforts in complement-pathway biology for tissue-targeted immune control. The company’s work is positioned within the broader biopharmaceutical sector, where precision immunology and biologics play an important role in addressing chronic diseases with limited treatment options. Based in Waltham, Massachusetts, Q32 Bio continues to operate as a research-focused company advancing specialized therapies from clinical development programs.

Sector
Healthcare
Industry
Biotechnology
CEO
Ms. Jodie Pope Morrison
Employees
25
Headquarters
Waltham, MA, United States

Frequently asked questions about Q32 Bio Inc.